In 2014, it was shown that a patient suffering from NSCLC harboring low-level amplification of the MET gene (i.e., MET/CEN7 ≥ 1.8 ratio ≤ 2.2, n = 1) had no response to the tyrosine kinase inhibitor crizotinib. This evidence concerns the gene MET and non-small cell lung carcinoma.